PO-506 The dynamics of HER2 status in esophageal adenocarcinoma

Abstract

IntroductionTrastuzumab, a monoclonal antibody against HER2, has become standard of care for metastatic HER2-overexpressing esophagogastric adenocarcinoma and is currently investigated as (neo)adjuvant treatment option in HER2-positive esophagogastric adenocarcinoma. The HER2 status is commonly determined on archived material of the primary tumour. However, this status may change over the course of treatment or disease progression. The aim of this study was to assess the dynamics of HER2 status in esophageal adenocarcinoma (EAC) in patients with resectable and recurrent disease, and to determine the associations of these changes with clinical outcome.Material and methodsDiscordance, defined as any change in HER2 status between matched biopsy and post-neoadjuvant chemoradiation therapy resection specimen (n=170), or between matched resection specimen and recurrence of patients not eligible for curative treatment (n=61), was determined using the standardised HER2 status scoring system. Clinically relevant positive discordance was defined as a change to HER2 positive status, as this would imply eligibility for HER2-targeted therapy.Results and discussionsA difference in HER2 status between biopsy and resection specimen and resection specimen and metachronous recurrence was observed in 2.1% (n=3) and 3.3% (n=2) of the paired cases, respectively. Clinically relevant discordance was detected in 1.4% (n=2) of the resectable patients and 1.6% (n=1) of the patients with recurrent disease. Patients with HER2-positive status tumours before start of neoadjuvant treatment showed better overall survival, but not statistically significant. No association between HER2 status discordance and survival was found.ConclusionClinically relevant HER2 status discordance was observed and in order to prevent under-treatment of patients, the assessment of HER2 status in the metastatic setting should preferably be performed on the most recently developed lesions if the previous HER2 assessment on archival material of the primary tumour was negative.